Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00480766 | A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED) | PHASE3 | COMPLETED | 173 | — | — | Jul 1, 2001 | Aug 1, 2003 | Aug 14, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0217/Duration of Treatment : 12 Months | DRUG | - |
Inclusion Criteria: * Man or woman aged 18 to 80 years, being treated with oral glucocorticoid (steroid), without vertebral fracture or prior osteoporotic fracture Exclusion Criteria: * Mentally or legally incompetent, pregnant, alcohol or drug dependence, history of heart disease, kidney disease...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | NA | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | — | Undisclosed |